December 5-7th, 2017

Miami, FL

REGISTER HERE

Resources

  • TN2

    Key Takeaway’s

    With oncolytic virotherapies becoming big news recently with transgene and randox signing a collaboration to develop innovative multifunctional oncolytic virotherapies for solid tumors, the reolysin combo given to the 1st patient in phase 1 trial for relapsing myeloma and news that amgen’s imlygic doubles response rate when added to checkpoint therapy all in the last month.

    download